iCAD Inc  

(Public, NASDAQ:ICAD)   Watch this stock  
Find more results for ICAD
9.09
+0.50 (5.82%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.67 - 9.49
52 week 5.16 - 14.11
Open 8.67
Vol / Avg. 133,543.00/83,836.00
Mkt cap 129.28M
P/E     -
Div/yield     -
EPS -0.65
Shares 14.22M
Beta 1.16
Inst. own 45%
Jul 30, 2014
Q2 2014 iCAD Inc Earnings Release
Jul 30, 2014
Q2 2014 iCAD Inc Earnings Call
Jul 15, 2014
iCAD Inc Business Update Call - Webcast
May 6, 2014
Q1 2014 icad, Inc Earnings Conference Call - Webcast
May 6, 2014
Q1 2014 icad, Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -2.23% -23.01%
Operating margin -5.40% -5.37%
EBITD margin - 1.98%
Return on average assets -1.06% -12.80%
Return on average equity -2.14% -31.03%
Employees 102 -
CDP Score - -

Address

Suite 100, 98 Spit Brook Road
NASHUA, NH 03062-5734
United States - Map
+1-603-8825200 (Phone)
+1-603-8803843 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

iCAD, Inc. (iCAD) is an advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a range of upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Its digital and MRI CAD products include advanced image analysis and workflow solutions in breast imaging (mammography), advanced image analysis and workflow solutions in MRI imaging - breast and prostate, and advanced image analysis and workflow solutions in CT Colonography. Its Film based products include products for converting mammography films to digital images. Its electronic brachytherapy products include electronic brachytherapy (Ebx) treatment for breast cancer. Effective July 15, 2014, iCAD Inc acquired DermEbx and Radion Inc.

Officers and directors

Lawrence Howard Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Kenneth M. Ferry President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin C. Burns Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
Age: 43
Bio & Compensation  - Reuters
Stacey M. Stevens Senior Vice President - Marketing and Strategy
Age: 46
Bio & Compensation  - Reuters
Jonathan Go Senior Vice President - Research and Development
Age: 51
Bio & Compensation  - Reuters
Robert L. Goodman M.D. Director
Age: 73
Bio & Compensation  - Reuters
Rachel Brem M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Anthony F. Ecock Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael S. Klein Independent Director
Age: 60
Bio & Compensation  - Reuters
Steven N. Rappaport Independent Director
Age: 65
Bio & Compensation  - Reuters